Achillion shares should be bought ahead of data, says Piper Jaffray Piper Jaffray recommends buying Achillion's stock ahead of data from its ACH-3102 + ribavarin for HCV in April. The firm was encouraged by interim data on ACH-3102 and continues to see the company as a likely takeout candidate. It maintains an Overweight rating on the shares.
News For ACHN From The Last 14 Days
Check below for free stories on ACHN the last two weeks.